SCGB 3A2

Drug Profile

SCGB 3A2

Alternative Names: CG1011; Recombinant human secretoglobin 3A2; SCGB3A2

Latest Information Update: 19 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Clarassance
  • Developer Therabron Therapeutics
  • Class Recombinant proteins
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bronchiectasis; Pulmonary fibrosis

Most Recent Events

  • 10 Oct 2013 Preclinical trials in Bronchiectasis in USA (Parenteral)
  • 10 Oct 2013 Preclinical trials in Pulmonary fibrosis in USA (Parenteral)
  • 07 Aug 2009 Clarassance establishes CRADA with the NIH’s National Cancer Institute for the development of SCGB 3A2 in Lung disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top